PaxMedica, Inc. announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer. In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica's pipeline products. The initial program underway is targeting antipurinergic drug therapies.

Dr. Schwabe has over 30 years of experience in the pharmaceutical industry. Dr. Schwabe worked in the CNS area at Ciba-Geigy, Novo Nordisk, J&J, Novartis and Sanofi in various capacities in clinical development, medical affairs and project management. Most recently, Dr. Schwabe served as Executive Vice President of Research and Development and Chief Medical Officer of Supernus Pharmaceuticals since 2012.

Previously, he was the Chief Operating Officer at DemeRx, a privately held biotech company working in the area of addiction. Dr. Schwabe received a PhD in clinical toxicology from the University of Munich, an MD degree from Ludwig-Maximilians-Universität München, Germany, and a Bachelor of Science in Chemistry from Florida International University and he completed a residency in Neurology from the Medical College of Wisconsin.